Press release
Gossamer Bio Announces Participation in the Guggenheim Healthcare Talks Neuro/Immunology Day
SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and
About this update from Gossamer Bio, Inc.
[{"type":"text","content":" SAN DIEGO--(BUSINESS WIRE)--\nGossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that Sheila Gujrathi, M.D., Chief Executive Officer and Co-Founder, will participate in a fireside chat at the Guggenheim Healthcare Talks Neuro/Immunology Day on Monday, November 18 at 1:00 p.m. ET.\n\n\nA live webcast of the presentation will be available on the “Events and Presentations” page in the “Investors” section of the company’s website at https://ir.gossamerbio.com. A replay of the webcast will be archived on the company’s website for 90 days following the presentation.\n\n\nAbout Gossamer Bio\n\n\nGossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20191114005228/en/\n\nFor Investors:\nArgot Partners\nTel 212.600.1902\[email protected]\n\n\nFor Media:\nArgot Partners\nDavid Rosen\nTel 212.600.1902\[email protected]\n\nSource: Gossamer Bio","length":3017,"tagName":"div"}]